Email this article 
Post a Comment Opportunities to predict effectiveness of antisecretory therapy in patients with gastroesophageal reflux disease
- Authors: Rabotyagova Y.S.1, Klyaritskaya I.L.1
-
Affiliations:
- Medical Academy named after S.I. Georgievsky
- Issue: Vol 10, No 1 (2018)
- Pages: 61-66
- Section: Reviews
- URL: https://journals.rcsi.science/vszgmu/article/view/8814
- DOI: https://doi.org/10.17816/mechnikov201810161-66
- ID: 8814
Cite item
Full Text
Abstract
To determine the factors that affect the effectiveness of gastroesophageal reflux disease therapy, a correlation analysis was performed that included the international GERD questionnaire, the hospital anxiety and depression score (HADS), and data on the polymorphism of cytochrome P450 2C19 in 136 patients with different variants gastroesophageal reflux disease (GERD): reflux esophagitis (RE), non-erosive reflux disease (NERD) and reflux hypersensitivity (RH). The presence of a strong negative relationship between the favorable outcome of PPI therapy and the GERD score was demonstrated after 4 weeks of therapy in the RE, NERD and RH groups (p < 0.001). When analyzing the relationship between the HADS scale and the effectiveness of therapy, a strong negative correlation was found only in the RE group (p < 0.001), the fact that the metabolic rate of the PPI moderately correlated with the favorable outcome of therapy in the RH and NERD groups (p < 0.05).
Full Text
##article.viewOnOriginalSite##About the authors
Yu. S. Rabotyagova
Medical Academy named after S.I. Georgievsky
Author for correspondence.
Email: yliyarabotyagova@gmail.com
Russian Federation, Simferopol
I. L. Klyaritskaya
Medical Academy named after S.I. Georgievsky
Email: yliyarabotyagova@gmail.com
Russian Federation, Simferopol
References
- El-Serag H, Sweet S, Winchester C, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871-80. doi: 10.1136/gutjnl-2012-304269.
- Маев И.В., Белый П.А., Лебедева Е.Г. Влияние полиморфизма гена CYP2C19 на эффективность использования ингибиторов протонной помпы в лечении гастроэзофагеальной рефлюксной болезни // Лечащий врач. – 2011. – Т. 7. – С. 93–95. [Maev IV, Belyj PA, Lebedeva EG. Vlijanie polimorfizma gena CYP2C19 na jeffektivnost’ ispol’zovanija ingibitorov protonnoj pompy v lechenii gastrojezofageal’noj refljuksnoj bolezni. Lechashhij vrach. 2011;7:93-95. (In Russ.)]
- Sachas G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton inhibitors. Aliment Pharmacol Ther. 2006;23(2):2-8. doi: 10.1111/j.1365-2036.2006.02943.x.
- Бордин Д.С. Что следует учитывать при выборе ингибитора протонной помпы больному ГЭРБ? // Медицинский альманах. – 2010. – № 1 (10). – С. 127–130. [Bordin DS. Chto sleduet uchityvat’ pri vybore ingibitora protonnoj pompy bol’nomu GJeRB? Medicinskij al’manah. 2010;1(10):127-130. (In Russ.)]
- Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Practice and Research. 2010;24(6):905-921.
- Hunt RH, Yuan Y, Yaghhoobi M. GERD: new strategies and new failures. J Clin Gastroenterol. 2007;41(suppl. 2):72-77.
Supplementary files
